A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers
Latest Information Update: 14 Oct 2024
At a glance
- Drugs Cetrelimab (Primary) ; Cetrelimab (Primary)
- Indications Bladder cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Janssen Research & Development; Janssen-Cilag
- 09 Oct 2024 Planned End Date changed from 24 Oct 2025 to 1 Oct 2025.
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 07 Nov 2023 Planned primary completion date changed from 24 Oct 2023 to 16 Nov 2023.